NYSE$STE
STERIS PLC · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
STERIS reported its financial results for the third quarter of fiscal year 2025, showing an increase in total revenue and net income from continuing operations.
STERIS plc announced strong financial results for its fiscal 2025 third quarter, with total revenue from continuing operations increasing by 6% to $1.4 billion. Net income from continuing operations rose to $173.6 million, and adjusted EPS increased to $2.32. The company also updated its fiscal 2025 outlook, primarily due to shifts in foreign currency rates.
- Total revenue from continuing operations increased 6% to $1.4 billion in Q3 fiscal 2025.
- Constant currency organic revenue from continuing operations also grew by 6%.
- As reported EPS from continuing operations increased to $1.75, while adjusted EPS rose to $2.32.
- Healthcare revenue grew 7% to $976.0 million, driven by improvements in consumables and service revenue.
Headline financials
Revenue & EPS history
STERIS · Revenue · Quarterly
$1.37B
Revenue by segment
STERIS · $1.59B total across 3 segments · Q4 2027
- Healthcare$1.14B—71.5%
- Applied Sterilization Technologies$289M—18.2%
- Life Sciences$163M—10.3%
Forward guidance
For fiscal 2025, STERIS expects as reported revenue to increase approximately 6% and adjusted earnings per diluted share to be in the range of $9.05 to $9.15. Capital expenditures are anticipated to be around $360 million, with free cash flow expected to be approximately $700 million.
Tailwinds
- Anticipated as reported revenue increase of approximately 6% for fiscal 2025.
- Constant currency organic revenue from continuing operations expected to be approximately 6%.
- Adjusted earnings per diluted share anticipated to be in the range of $9.05 to $9.15.
- Free cash flow expected to be approximately $700 million.
- Effective tax rate assumed to be approximately 23%.
Headwinds
- Updated outlook reflects a significant shift in foreign currency based on forward rates through March 31, 2025, which is expected to be unfavorable to revenue.
- Lower than anticipated revenue for capital equipment in the Healthcare segment.
- Approximately ten cent negative impact on adjusted EPS from currency.
- Outlook does not reflect any potential impact from new tariffs.
- Capital expenditures are anticipated to be approximately $360 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.5%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+12.9%
Q4 2014
Best reaction
-11.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +0.0% | +7.2% | +2.8% | |
| Q3 2026 | -7.7% | -7.4% | -12.8% | |
| Q2 2026 | +7.0% | +9.7% | +8.3% | |
| Q4 2025 | +8.6% | +10.1% | +6.1% | |
| Q3 2025 | +2.1% | +1.1% | +5.4% | |
| Q2 2025 | -5.2% | -2.5% | -5.1% | |
| Q1 2025 | -1.8% | -0.8% | +0.5% | |
| Q4 2024 | +6.2% | +9.2% | +6.6% | |
| Q3 2024 | -2.5% | -0.4% | +3.4% | |
| Q2 2024 | -5.1% | -8.4% | -7.1% | |
| Q1 2024 | +1.0% | +0.2% | +1.8% | |
| Q4 2023 | +11.2% | +12.7% | +10.6% | |
| Q3 2023 | -11.4% | -9.5% | -18.2% | |
| Q2 2023 | +3.5% | +2.6% | +17.3% | |
| Q1 2023 | -8.8% | -4.7% | -10.0% | |
| Q4 2022 | +1.4% | +1.2% | +2.6% | |
| Q3 2022 | +4.6% | +1.3% | -2.1% | |
| Q2 2022 | -5.5% | -4.8% | -6.4% | |
| Q1 2022 | +0.6% | +1.2% | +0.2% | |
| Q4 2021 | -3.6% | -3.1% | +1.9% | |
| Q3 2021 | -1.9% | -1.7% | -8.1% | |
| Q2 2021 | -0.5% | +2.5% | +8.8% | |
| Q1 2021 | -1.0% | -3.4% | +2.5% | |
| Q4 2020 | +1.2% | +7.0% | +1.8% | |
| Q3 2020 | +6.1% | +10.2% | -5.0% | |
| Q2 2020 | +2.3% | +2.6% | +8.4% | |
| Q1 2020 | +3.0% | +4.1% | +3.0% | |
| Q4 2019 | +1.1% | +3.2% | +10.2% | |
| Q3 2019 | +1.9% | +3.1% | +3.6% | |
| Q2 2019 | +7.0% | +7.4% | +5.4% | |
| Q1 2019 | -0.7% | -1.1% | -1.9% | |
| Q4 2018 | +4.7% | +4.6% | +8.6% | |
| Q3 2018 | -4.7% | -2.8% | +7.8% | |
| Q2 2018 | -6.0% | -6.6% | -3.9% | |
| Q1 2018 | +4.9% | +3.3% | +5.8% | |
| Q4 2017 | +1.4% | -0.4% | +6.4% | |
| Q3 2017 | -6.5% | -5.7% | -3.4% | |
| Q2 2017 | -3.0% | +0.5% | -2.0% | |
| Q1 2017 | -1.6% | -1.9% | -2.0% | |
| Q4 2016 | -0.5% | — | — | |
| Q3 2016 | -1.9% | — | — | |
| Q2 2016 | +6.4% | — | — | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +3.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +12.9% | — | — | |
| Q3 2014 | +0.5% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2014 | -3.6% | — | — | |
| Q4 2013 | +8.3% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q2 2013 | +1.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q2 2012 | -4.4% | — | — | |
| Q4 2011 | +0.3% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q2 2010 | +0.8% | — | — | |
| Q4 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro